ESMO: 1-Year of Adjuvant Trastuzumab Remains Standard of Care for HER2-Positive Early Breast Cancer

Share this content:
(ChemotherapyAdvisor) – Administering adjuvant trastuzumab for 1 year—currently considered standard of care—remains optimal in women with HER2-positive early breast cancer, results of two studies presented during the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria concluded.

Long-awaited results from HERA, the only phase 3 randomized trial to investigate whether longer duration of trastuzumab might further improve efficacy, confirmed disease-free survival (DFS) to be comparable for patients who received 1 or 2 years of treatment (unadjusted HR 0.99; 95% CI 0.85–1.14; P=0.8588), noted Richard Gelber, PhD, of Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, and colleagues.

Overall survival (OS) was also comparable between the two arms, (HR 1.05; 95% CI 0.86–1.28; P=0.6333), as was time to distant recurrence.

The Breast International Group trial, initiated in 2001, randomly assigned 5,102 women with HER2-positive early breast cancer after completion of primary therapy (eg, surgery, chemotherapy, and radiotherapy as indicated) to trastuzumab every 3 weeks for 1 year (n=1,552), 2 years (n=1,553), or observation.

Results of the landmark efficacy analysis presented at ESMO also noted that compared with observation, the durable benefit in DFS and OS for both 1 year and 2 years of trastuzumab therapy remained stable at 8 years of median follow-up. The primary cardiac end point was comparable between the two arms (0.96% for 2 years vs 0.83% for 1 year); however, the secondary cardiac end point was higher in the 2-year arm (7.17% vs 4.10%, respectively).

“The key message for 2012 is that 1 year of treatment with trastuzumab remains the standard of care for HER2 positive early breast cancer patients,” Dr. Gelber said. “While extending the duration of trastuzumab administration to 2 years did not significantly improve outcome compared with 1 year trastuzumab, ongoing trials are testing whether combining trastuzumab with other anti-HER2 agents (for example, pertuzumab or lapatinib) might further benefit patients with HER2-positive early breast cancer,” he noted.

The second study, instituted by the French National Cancer Institute, compared 6 to 12 months of trastuzumab in a DFS non-inferiority schema in more than 3,380 patients. Median follow-up was 42.5 months.

“The trial results are inconclusive for this non-inferiority hypothesis,” said Prof. Xavier Pivot, of the Université de Franche Comté, France. “However, despite the inconclusive result in terms of non-inferiority, the HR of 1.28 suggests a trend favoring 12 months,” he added. Subgroup analyses to determine who might benefit from 6 vs 12 months of treatment will be presented later this year.

Abstracts (LBA5_PR and LBA6_PR)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs